Dr Reddys Laboratories (RDY) Short term Debt (2017 - 2025)
Dr Reddys Laboratories has reported Short term Debt over the past 9 years, most recently at $439.3 million for Q1 2025.
- For Q1 2025, Short term Debt rose 2691.56% year-over-year to $439.3 million; the TTM value through Mar 2025 reached $439.3 million, up 2691.56%, while the annual FY2025 figure was $10.0 million, 93.46% down from the prior year.
- Short term Debt for Q1 2025 was $439.3 million at Dr Reddys Laboratories, up from $15.7 million in the prior quarter.
- Over five years, Short term Debt peaked at $439.3 million in Q1 2025 and troughed at $11.8 million in Q1 2021.
- A 5-year average of $183.4 million and a median of $89.9 million in 2023 define the central range for Short term Debt.
- Biggest five-year swings in Short term Debt: crashed 94.78% in 2021 and later skyrocketed 2939.46% in 2022.
- Year by year, Short term Debt stood at $11.8 million in 2021, then skyrocketed by 2939.46% to $360.2 million in 2022, then tumbled by 75.04% to $89.9 million in 2023, then tumbled by 82.49% to $15.7 million in 2024, then skyrocketed by 2691.56% to $439.3 million in 2025.
- Business Quant data shows Short term Debt for RDY at $439.3 million in Q1 2025, $15.7 million in Q1 2024, and $89.9 million in Q1 2023.